Since the launch of Viagra in 1998, PDE5 inhibitors have been the frontline pharmacotherapy for treating erectile dysfunction. Phosphodiesterase type 5 (PDE5) inhibitors, including sildenafil, tadalafil, vardenafil, and avanafil, can help achieve an erection in about 65% of men with erectile dysfunction.
A new drug, pudafensine (iped2015), is currently in clinical trials. This is the first oral drug based on a completely different principle and is specifically targeted at men who do not respond to PDE5 inhibitors. According to the developer, initiator constraints“Fudafensine enhances the natural erectile response through the dual action of a central effect to initiate erection and a peripheral effect to enhance erection through smooth muscle relaxation.”
“Fudafensin demonstrated positive results in the Phase IIb clinical trial of Fudafensin (IP2015) for the treatment of erectile dysfunction (ED). Analysis of study data demonstrated statistically significant and clinically relevant efficacy in erectile dysfunction-related endpoints and no serious adverse events were observed.”
Although early results have been promising, general availability of drugs in clinical trials is still years away.
REDEYE Stock Research “We believe that Initiator Pharma’s most advanced program, pudafensine (IPED2015), is well-positioned to fundamentally change the erectile dysfunction (ED) treatment paradigm,” it said in an August 2023 report on Initiator Pharma. that
Active Pharmaceutical Ingredient (API) IP2015 has a unique dual mechanism of action.
It enhances the patient's libido and increases penile blood flow.
It sets us apart from our competitors and gives us a wider reach.”
We contacted Initiator Pharma for more information about further clinical trials, but did not receive a response.
Related Reading
Oral Medications for Erectile Dysfunction: Comparison of Viagra, Cialis, and Levitra.